GlassScriptPhysician profile
Joshua Starr
NPI 1588005482
$2,476.81
in general payments reported to CMS, 2019-2025
26 companies · $787 in 2025
The $787 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.42 · 2022: $87.98 · 2023: $395 · 2024: $1,179 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.36 | 2023-2025 | Ubrelvy, Qulipta, Viberzi |
| Lilly USA, LLC | $365.52 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $266.21 | 2022-2025 | |
| Novo Nordisk INC | $230.42 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $156.40 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.31 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $143.55 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $91.11 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $90.55 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Corcept Therapeutics | $73.73 | 2024-2025 | Korlym |
| Axsome Therapeutics, INC. | $66.60 | 2023-2025 | Auvelity |
| Lundbeck LLC | $64.83 | 2024-2025 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $32.38 | 2021-2022 | |
| Amgen INC. | $30.68 | 2024 | Krystexxa |
| Neurocrine Biosciences, INC. | $29.33 | 2024 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.03 | 2024 | |
| Phathom Pharmaceuticals, INC. | $28.79 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $25.29 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $24.92 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $24.55 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.43 | 2023 | Jardiance |
| Sumitomo Pharma America, INC. | $22.58 | 2024 | Gemtesa |
| Seqirus USA INC | $22.44 | 2024 | Flucelvax, Fluad |
| Dynavax Technologies Corporation | $18.45 | 2024 | Heplisav-B |
| Dexcom, INC. | $17.23 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $14.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.